While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.
Roche attributed the stagnation to significant pricing pressures stemming from China’s healthcare reform agenda, including an expansion of volume-based procurement (VBP) programs. (Shutterstock)
Key Takeaways
Roche’s diagnostics sales remained flat at $4.2bn in Q1 2025 due to healthcare reforms and volume-based procurement initiatives in China.
Even as Roche continues to view China as a core strategic market, its diagnostics division posted flat sales in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.
The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.
